Correction to: Topical Glycopyrronium Tosylate in Primary Axillary Hyperhidrosis: A Profile of Its Use

被引：0
|
作者：
Yvette N. Lamb
机构：
[1] Springer Nature,
来源：
Clinical Drug Investigation | 2020年 / 40卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The original article has been corrected.
引用
收藏
页码：103 / 103
相关论文
共 50 条
  • [31] Glycopyrronium tosylate in pediatric primary axillary hyperhidrosis: Post hoc analysis of efficacy and safety findings by age from two phase three randomized controlled trials (vol 36, pg 89, 2016)
    Hebert, A. A.
    Glaser, D. A.
    Green, L.
    PEDIATRIC DERMATOLOGY, 2019, 36 (03) : 424 - 424
  • [32] Safety and efficacy of topical formulations containing 0.5, 1 and 2% glycopyrronium bromide in patients with primary axillary hyperhidrosis: a randomized, double-blind, placebo-controlled study
    Masur, C.
    Soeberdt, M.
    Kilic, A.
    Knie, U.
    Abels, C.
    BRITISH JOURNAL OF DERMATOLOGY, 2020, 182 (01) : 229 - 231
  • [33] Reversible anisocoria due to inadvertent ocular exposure to topical anticholinergic treatment for primary axillary hyperhidrosis
    Pashaei-Marandi, Aryan
    Assam, Jed H.
    Arnold, Anthony
    Lee, Andrew G.
    Bonelli, Laura
    CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE, 2019, 54 (06): : E300 - E302
  • [34] A new aluminum sesquichlorhydrate topical foam for the treatment of axillary and/or palmar primary hyperhidrosis: A preliminary report
    Micali, Giuseppe
    Tedeschi, Aurora
    Lacarrubba, Francesco
    Umana, Marianna
    Di Mauro, Paola
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2013, 68 (04) : AB40 - AB40
  • [35] An open-label tolerability and efficacy study of an aluminum sesquichlorhydrate topical foam in axillary and palmar primary hyperhidrosis
    Innocenzi, Daniele
    Ruggero, Arianna
    Francesconi, Lidia
    Lacarrubba, Francesco
    Nardone, Beatrice
    Micali, Giuseppe
    DERMATOLOGIC THERAPY, 2008, 21 : S27 - S30
  • [36] Efficacy and Safety Results from a randomized controlled Phase-3a Trial of 1% Glycopyrronium Bromide Cream for the Treatment of primary axillary Hyperhidrosis
    Abels, Christoph
    Soeberdt, Michael
    Kilic, Ana
    Reich, Hubert
    Knie, Ulrich
    Masur, Clarissa
    Szeimies, Rolf-Markus
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2022, 20 : 8 - 9
  • [37] EFFICACY AND SAFETY RESULTS FROM A RANDOMIZED CONTROLLED PHASE 3A STUDY OF 1% GLYCOPYRRONIUM BROMIDE CREAM FOR THE TREATMENT OF PRIMARY AXILLARY HYPERHIDROSIS
    Abels, Christoph
    Soeberdt, Michael
    Kilic, Ana
    Reich, Hubert
    Knie, Ulrich
    Masur, Clarissa
    Szeimies, Rolf-Markus
    ACTA DERMATO-VENEREOLOGICA, 2022, 102 : 54 - 54
  • [38] Efficacy and Safety of 1% Glycopyrronium Bromide Cream for the Treatment of severe primary axillary Hyperhidrosis (PAHH) in Long-term Application (72 Weeks)
    Szeimies, Rolf-Markus
    Abels, Christoph
    Kilic, Ana
    Reich, Hubert
    zur Wiesche, Erik Schulze
    Masur, Clarissa
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 12 - 13
  • [39] Botulinum toxin type a versus topical 20% aluminum chloride for the treatment of moderate to severe primary focal axillary hyperhidrosis
    Flanagan, Katherine H.
    King, Rosemary
    Glaser, Dee Anna
    JOURNAL OF DRUGS IN DERMATOLOGY, 2008, 7 (03) : 221 - 227
  • [40] Correction to: Metreleptin in lipodystrophy: a profile of its use
    Emma Deeks
    Drugs & Therapy Perspectives, 2019, 35 : 527 - 527
12345